GB1039113A — New n-substituted lactams
Assigned to UCB SA · Expires 1966-08-17 · 60y expired
What this patent protects
The invention comprises compounds of formula <FORM:1039113/C2/1> wherein n is 3, 4 or 5 and R is a group -CH2)mCONR1R11, in which m is 0, 1 or 2, R1 is a hydrogen atom or an alkyl, cycloalkyl, alkenyl, alkynyl or aryl radical and R11 is a hydrogen atom or an alkyl radical, …
USPTO Abstract
The invention comprises compounds of formula <FORM:1039113/C2/1> wherein n is 3, 4 or 5 and R is a group -CH2)mCONR1R11, in which m is 0, 1 or 2, R1 is a hydrogen atom or an alkyl, cycloalkyl, alkenyl, alkynyl or aryl radical and R11 is a hydrogen atom or an alkyl radical, or the group -NR1R11 forms a heterocyclic ring, and their preparation by (a) reaction of an N-unsubstituted lactam with an alkali metal hydride, followed by treatment with an o -chloro-alkyl-amine, (b) reaction of a compound wherein R is a group -(CH2)mCOOAlk and Alk is a C1- 5 alkyl group with an amine NHR1R11, or (c) reaction of an N-substituted lactam with an isocyanate R1NCO. The compounds of the invention have an anti-histaminic and anti-cholinergic activity.
Drugs covered by this patent
- Briviact (BRIVARACETAM) · UCB
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.